479 related articles for article (PubMed ID: 21733058)
1. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Bosi E; Ellis GC; Wilson CA; Fleck PR
Diabetes Obes Metab; 2011 Dec; 13(12):1088-96. PubMed ID: 21733058
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Seino Y; Miyata Y; Hiroi S; Hirayama M; Kaku K
Diabetes Obes Metab; 2012 Oct; 14(10):927-36. PubMed ID: 22583697
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
Kaku K; Itayasu T; Hiroi S; Hirayama M; Seino Y
Diabetes Obes Metab; 2011 Nov; 13(11):1028-35. PubMed ID: 21682833
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Pratley RE; Reusch JE; Fleck PR; Wilson CA; Mekki Q;
Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
[TBL] [Abstract][Full Text] [Related]
5. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
Del Prato S; Camisasca R; Wilson C; Fleck P
Diabetes Obes Metab; 2014 Dec; 16(12):1239-46. PubMed ID: 25132212
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study.
Kaku K; Katou M; Igeta M; Ohira T; Sano H
Diabetes Obes Metab; 2015 Dec; 17(12):1198-201. PubMed ID: 26277887
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
Nauck MA; Ellis GC; Fleck PR; Wilson CA; Mekki Q;
Int J Clin Pract; 2009 Jan; 63(1):46-55. PubMed ID: 19125992
[TBL] [Abstract][Full Text] [Related]
10. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
[TBL] [Abstract][Full Text] [Related]
11. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Rosenstock J; Wilson C; Fleck P
Diabetes Obes Metab; 2013 Oct; 15(10):906-14. PubMed ID: 23531118
[TBL] [Abstract][Full Text] [Related]
12. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.
Van Raalte DH; van Genugten RE; Eliasson B; Möller-Goede DL; Mari A; Tura A; Wilson C; Fleck P; Taskinen MR; Smith U; Diamant M
Eur J Endocrinol; 2014 Apr; 170(4):565-74. PubMed ID: 24421302
[TBL] [Abstract][Full Text] [Related]
13. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
[TBL] [Abstract][Full Text] [Related]
14. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
Rosenstock J; Rood J; Cobitz A; Huang C; Garber A
Diabetes Obes Metab; 2006 Nov; 8(6):643-9. PubMed ID: 17026488
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial in mainland China].
Pan C; Li W; Zeng J; Li C; Yang J; Ji Q; Lu J; Lyu X; Li X; Qu S; Xu X; Xue Y; Li L; Jiang Z; Zheng B; Bu R; Han P; Liu Y; Liu J; Peng Y; Liu X; Liu Z; Yan L; Lei M; Li X; Song Q; Shi B; Gu W; Li Z
Zhonghua Nei Ke Za Zhi; 2015 Nov; 54(11):949-53. PubMed ID: 26759214
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study.
Kim JM; Kim SS; Kim JH; Kim MK; Kim TN; Lee SH; Lee CW; Park JY; Kim ES; Lee KJ; Choi YS; Kim DK; Kim IJ
Diabetes Metab J; 2020 Feb; 44(1):67-77. PubMed ID: 31339011
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.
Pratley RE; Fleck P; Wilson C
Diabetes Obes Metab; 2014 Jul; 16(7):613-21. PubMed ID: 24400655
[TBL] [Abstract][Full Text] [Related]
18. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
Pratley RE; McCall T; Fleck PR; Wilson CA; Mekki Q
J Am Geriatr Soc; 2009 Nov; 57(11):2011-9. PubMed ID: 19793357
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
Home PD; Shamanna P; Stewart M; Yang F; Miller M; Perry C; Carr MC
Diabetes Obes Metab; 2015 Feb; 17(2):179-87. PubMed ID: 25406730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
